Detalhe da pesquisa
1.
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Cancer
; 121(5): 716-23, 2015 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25355245
2.
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
J Clin Oncol
; 36(22): 2259-2266, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29584548
3.
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Leuk Res
; 35(12): 1637-43, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21816470
4.
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Cancer
; 116(19): 4541-8, 2010 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20572046